2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 984

Tofacitinib Inhibits Inflammation and New Bone Formation in Murine Spondyloarthritis but Does Not Adversely Inhibit Normal Human MSC Function
Abstract Number: 985

Improved Survival in Systemic Lupus Erythematosus: A Population-Based Study
Abstract Number: 986

Application of New EULAR Definitions of Remission in SLE: Durable 1-Year Remission Is Rare
Abstract Number: 987

Pre-Emptive Renal Transplantation Among End Stage Renal Disease Patients with and without SLE
Abstract Number: 988

Factors Associated with Renal Remission, Relapse and Long-Term Renal Function Decline in Lupus Nephritis Treated with Combined Prednisolone and Mycophenolate Mofetil (MMF) or Tacrolimus (Tac)
Abstract Number: 989

Economic Evaluation of Lupus Nephritis in an International Inception Cohort: Comparing the Hospitalization, Medication, Dialysis, and Procedure Costs of Those with and without Nephritis
Abstract Number: 990

Performance of the Systemic Lupus International Collaborating Clinic Classification Criteria Versus the 1982 and Revised 1997 American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus: A Population-Based Study
Abstract Number: 991

CaMK4 Facilitates Recruitment of IL-17 Producing Cells to Target Organs through the CCR6/CCL20 Axis in Th17-Driven Inflammatory Diseases
Abstract Number: 992

Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus
Abstract Number: 993

Failure in Nutrient Sensing Supports mTOR Hyperactivity and Proinflammatory Functions in T Cells from Patients with Rheumatoid Arthritis
Abstract Number: 994

Th17/Tfh Cell Predict Disease Severity in Rheumatoid Arthritis Patients Receiving TNF Inhibitor Therapy
Abstract Number: 995

In Rheumatoid Arthritis Only a Few Expanded T-Cell Clones Dominate in Joint Inflammation: A Study in Seven RA Patients Undergoing Paired Synovial Tissue Biopsies in Multiple Joints
Abstract Number: 996

Metabolic Control of Invariant Natural Killer T Cell Function
Abstract Number: 997

Feasibility and Influential Factors in Performing Self-Evaluation of DAS28 with Smart System of Disease Management (SSDM) By RA Patient in China
Abstract Number: 998

A Psychometric Analysis of the Social Interaction Anxiety Scale (SIAS-6) in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].